Incyte Corp
Research Incyte Corp (INCY) on Bullrun: valuation model: 4.0% undervalued, market cap USD 22.38B, P/E 14.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINCY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal4.0% undervalued
- Market capUSD 22.38B
- P/E14.2
- Financial periodQ2 2026
- RevenueUSD 1.67B
- Net incomeUSD 585.61M
- Free cash flowUSD 495.25M
- Gross margin93.7%
Valuation Snapshot
Bullrun's latest valuation model marks Incyte Corp as 4.0% undervalued; latest market cap is USD 22.38B; P/E is 14.2.
Peer valuation comparison
Latest P/E is 14.19x versus a Healthcare sector median of 24.6x (42.3% below).
Latest P/E is 14.19x versus a United States median of 23.85x (40.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 5.14B | USD 1.29B | USD 1.33B | 92.8% | 6.41 | USD 3.10B | USD 40.41M | USD 5.17B |
| FY2024 | USD 4.24B | USD 32.60M | USD 235.17M | 92.6% | 0.15 | USD 1.69B | USD 43.54M | USD 3.45B |
| FY2023 | USD 3.70B | USD 597.60M | USD 449.00M | 93.1% | 2.65 | USD 3.21B | USD 38.29M | USD 5.19B |
| FY2022 | USD 3.39B | USD 340.70M | USD 892.11M | 93.9% | 1.52 | USD 2.95B | USD 41.46M | USD 4.37B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 22.38B | 14.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 19.60B | 15.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.36B | 255.8 | n/a | n/a |
| 2023 | 2023-12-29 | USD 14.07B | 33.4 | n/a | n/a |
| 2022 | 2022-12-30 | USD 17.87B | 20.4 | n/a | n/a |
| 2021 | 2021-12-31 | USD 16.23B | 17.2 | n/a | n/a |
About Incyte Corp
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia;
ETFs that hold Incyte Corp
Incyte Corp is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| JPM Global Equity Multi-Factor UCITS ETF USD Acc | 0.34% | 0.19% |
| First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation | 3.47% | 0.60% |
| L&G Pharma Breakthrough UCITS ETF | 3.14% | 0.49% |
| JPM GLOBAL EQUITY MULTI-FACTOR UCITS ETF - USD (DIST) | 0.34% | 0.19% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Incyte Corp overvalued or undervalued?
Bullrun's valuation model currently marks Incyte Corp as 4.0% undervalued.
What is Incyte Corp's market cap?
Incyte Corp's market capitalization is USD 22.38B.
What is Incyte Corp's P/E ratio?
Incyte Corp's price-to-earnings (P/E) ratio is 14.2.
What does Incyte Corp do?
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.